Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET

Company Participants

Nichol Ochsner - VP, Investor Relations
Neil McFarlane - President & CEO
LaDuane Clifton - CFO, Secretary & Treasurer
Christal Mickle - Chief Development Officer

Conference Call Participants

Oren Livnat - H.C. Wainwright
Jonathan Aschoff - ROTH MKM
Sumant Kulkarni - Canaccord
Louise Chen - Cantor Fitzgerald
Oren Livnat - H.C. Wainwright

Operator

Good afternoon, everyone. Thank you for joining the Zevra Therapeutics' Q4 2023 Corporate Updates and Financial Results Call. Today's call is being recorded. It will be made available the company's website following the conclusion of the call. With that, I will now turn the call over to Nichol Ochsner, Vice President of Investor Relations and Corporate Communications for Zevra Therapeutics.

Nichol Ochsner

Good afternoon, and thank you for joining us today to review Zevra Therapeutics' progress in the fourth quarter and full year of 2023, outlining our clinical advances, operational achievements and financial results.

Before we get started, let me take a moment to provide some important information. I encourage you to access the news release which was just published and available in the Investor Release section of Zevra's website. As we proceed with this call, it's important to highlight that today's discussion will include forward-looking statements. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties and other significant factors that may to actual results differing materially from the projections made. Please refer to the Risk Factors section in our most recent quarterly reports on Form 10-Q and our other filings with the SEC and annual report on Form 10-K.

I'm pleased to welcome Zevra's management team members participating in today's call. I'm joined by Neil McFarlane, President and Chief Executive Officer; LaDuane Clifton, our Chief Financial Officer, Joshua Schafer, our Chief Commercial Officer and EVP of Business Development; Christal Mickle, our Chief Development Officer; and Adrian Quartel, our Chief Medical Officer.

Now I'll turn the call over to Neil.

Neil McFarlane

Thank you, Nichol. And thank you all for making the time to join us today.

During the fourth quarter and into 2024, we made solid progress transforming Zevra into a commercial stage company. On our last call, we announced that we were focused on 3 key priorities: First, to close the Acer acquisition and deliver value to patients by commercializing OLPRUVA. Second, to resubmit the arimoclomol NDA. Third, to complete the Phase II trial in idiopathic hypersomnia and prepare to advance KP1077 into Phase III. I'm happy to report that we executed on all of these objectives, and I would like to take the opportunity to recognize the extraordinary effort from our entire team to deliver for people living with rare diseases.